



## Foghorn Therapeutics to Participate in Two Upcoming Virtual Investor Conferences

September 1, 2021

CAMBRIDGE, Mass., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Foghorn Therapeutics Inc. (Nasdaq: FHTX), a clinical stage biotechnology company pioneering a new class of medicines that modulate gene expression through selectively targeting the chromatin regulatory system, today announced that Foghorn management will participate in two upcoming virtual investor conferences.

### Events:

#### **Morgan Stanley Virtual Annual Global Healthcare Conference**

Format: Fireside Chat and investor 1x1 meetings

Thursday, September 9, 2021

11:45am ET

Please find a link to the presentation [here](#). A replay will be available for 90 days.

#### **H.C. Wainwright 23<sup>rd</sup> Annual Global Investment Conference**

Format: Presentation and investor 1x1 meetings

Monday, September 13, 2021

All company presentations will be available on-demand beginning at 7:00am ET

Please find a link to the presentation [here](#).

A webcast of both presentations can also be accessed under "Events & Presentations" in the Investors section of the Company's website, [www.foghornrx.com](http://www.foghornrx.com)

### About Foghorn Therapeutics

Foghorn<sup>®</sup> Therapeutics is discovering and developing a novel class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Through its proprietary scalable Gene Traffic Control<sup>®</sup> platform, Foghorn is systematically studying, identifying and validating potential drug targets within the chromatin regulatory system. The company is developing multiple product candidates in oncology.

### Media Contact:

Fanny Cavalié, Foghorn Therapeutics Inc.

[fcavalié@foghornrx.com](mailto:fcavalié@foghornrx.com)

Gregory Kelley, Ogilvy

[gregory.kelley@ogilvy.com](mailto:gregory.kelley@ogilvy.com)

### Investor Relations Contact:

Ben Strain, Foghorn Therapeutics Inc.

[bstrain@foghornrx.com](mailto:bstrain@foghornrx.com)

Hans Vitzthum, LifeSci Advisors

617-430-7578

[hans@lifesciadvisors.com](mailto:hans@lifesciadvisors.com)



Source: Foghorn Therapeutics, Inc.